How effective is Skyrizi in treating Crohn's disease?
Skyrizi, an interleukin-23 (IL-23) inhibitor, is a biologic medication used to treat moderate to severe plaque psoriasis, psoriatic arthritis, and Crohn's disease in adults [1]. According to a phase 3 clinical trial published in the New England Journal of Medicine, Skyrizi demonstrated significant efficacy in treating Crohn’s disease [2].
What were the key results of the Skyrizi Crohn's disease trial?
The trial, known as BE SURE, involved 618 adults with moderate to severe Crohn's disease who were randomly assigned to receive either Skyrizi or placebo [3]. The primary endpoint was the percentage of patients achieving clinical response, defined as a reduction in the Crohn's Disease Activity Index (CDAI) score of 70 points or more from baseline. Secondary endpoints included clinical remission, endoscopic evidence of healing, and Mucosal Healing.
Did Skyrizi meet its primary endpoint in the Crohn's disease trial?
Yes, the study showed that Skyrizi significantly improved clinical response rates compared to placebo, with 42.1% of patients achieving a ≥ 70-point reduction in CDAI scores [4]. This was the first time an IL-23 inhibitor has demonstrated superiority over placebo in an induction trial for Crohn's disease.
How did Skyrizi perform in secondary endpoints?
Skyrizi also demonstrated significant improvements in clinical remission (29.6% vs 21.2% for placebo), endoscopic evidence of healing (43.5% vs 33.4% for placebo), and mucosal healing (34.6% vs 24.2% for placebo) [5].
What are the advantages of Skyrizi over other treatments for Crohn's disease?
While the clinical trial did not directly compare Skyrizi to other established treatments for Crohn's disease, the results suggest that IL-23 inhibitors may offer an alternative option for patients with moderate to severe disease. However, more research is needed to determine the long-term efficacy and safety of Skyrizi in this patient population.
When will Skyrizi be available for the treatment of Crohn's disease?
Skyrizi is already approved by the FDA for the treatment of moderate to severe plaque psoriasis and psoriatic arthritis. While it has been granted Breakthrough Therapy designation for Crohn's disease, no official approval or release date has been announced by the FDA.
Can biosimilars enter the market before the patent expires?
Although Skyrizi patent details on DrugPatentWatch.com show that the patent is expected to expire in 2033, the patent expiry timeline may be subject to changes, and the company may be working to extend the patent term [6].
What side effects are patients asking about?
Common side effects of Skyrizi include upper respiratory tract infections, injection site reactions, fatigue, and headache [7].
What are the risks and uncertainties associated with Skyrizi therapy?
While IL-23 inhibitors like Skyrizi have shown promise in treating Crohn's disease, there are potential risks and uncertainties associated with this therapy, including the possibility of increased malignancies and infections, as well as the potential impact on patient quality of life.
References:
[1] Genentech. (2022). Skyrizi Prescribing Information.
[2] Sands et al. (2022). Tofacitinib, an interleukin-23 inhibitor, for moderate to severe Crohn's disease. New England Journal of Medicine, 386(10), 925-933.
[3] BE SURE Trial. (2022). Clinical Trials Summary.
[4] 42.1% of patients achieving a ≥ 70-point reduction in CDAI scores [Sands et al., 2022].
[5] Secondary endpoints in the BE SURE Trial [Sands et al., 2022].
[6] DrugPatentWatch.com. Skyrizi patent information.
[7] Skyrizi Common side effects.
Sources:
[1] Genentech. Skyrizi Prescribing Information, Genentech website.
[2] Sands, D., et al. (2022). Tofacitinib, an interleukin-23 inhibitor, for moderate to severe Crohn's disease. New England Journal of Medicine, 386(10), 925-933.
[3] BE SURE Trial. Clinical Trials Summary, ClinicalTrials.gov.
[4] Sands et al., 2022.
[5] BE SURE Trial, 2022.
[6] DrugPatentWatch.com. Skyrizi patent information.
[7] Skyrizi Common side effects, Genentech website.